Skip to content

    Recently Viewed

      Listening...

      Collage depicting innovations from Johnson & Johnson around Ebola, bladder cancer, HIV and more

      Johnson & Johnson named a 2020 Fortune World’s Most Admired Company.

      Innovativeness and a commitment to social responsibility are just some of the respected attributes that helped the company land on the prestigious list for another year.

      Share Article
      share to

      For the 18th year, Johnson & Johnson has been named to Fortune’s list of the World’s Most Admired Companies. Johnson & Johnson also placed #1 in the Pharmaceutical category worldwide for the seventh consecutive year.

      To compile the international list, Fortune magazine partners with consulting firm Korn Ferry to survey industry analysts, as well as top executives and directors from Fortune 1000, Global 500 and other major non-U.S. companies. Their remit: identify companies with the strongest reputations based on a mix of nine attributes, including innovativeness, social responsibility to the community and the ability to attract and retain talented people.

      In 2019, to help combat the world’s second worst outbreak of Ebola on record, the company committed to donate up to 500,000 doses of an investigational Janssen vaccine regimen to the Democratic Republic of the Congo.

      A year of groundbreaking work from a world’s most admired company

      One of the key tenets in Johnson & Johnson’s guiding mission statement, Our Credo, is a responsibility to be a consistent positive force as it helps tackle some of the world’s most pressing unmet healthcare needs.

      The company marked many positive milestones in this regard in 2019, including the U.S. Food and Drug Administration (FDA) approval of a treatment from the Janssen Pharmaceutical Companies of Johnson & Johnson that may help provide more hope for some patients living with metastatic urothelial cancer.

      Johnson & Johnson also made a commitment to donate up to 500,000 doses of an investigational Janssen vaccine regimen to the Democratic Republic of the Congo to help combat the world’s second worst outbreak of Ebola on record. In 2019, it also launched the Mosaico trial at approximately 55 clinical trial sites across North America, South America and Europe to evaluate a mosaic-based vaccine concept for HIV prevention.

      The company culture of innovation isn’t just limited to scientific research and development either. After appearing on its list for more than three decades, Johnson & Johnson nabbed the #1 spot on Working Mother‘s 100 Best Companies List in 2019 for its vast variety of forward-thinking family benefits, from generous parental leave for moms and dads to backup dependent care support.

      Johnson & Johnson is always striving to help improve the trajectory of health for humanity—and the company is proud to be recognized for this work by being named a World’s Most Admired Company.


      More ways Johnson & Johnson is helping change the world

      Read the 2021 Health for Humanity Report to see how the company is putting health and wellness in reach of people everywhere.

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Health & wellness
       Blue latex gloved hand pointing at a brain MRI scan to pinpoint brain circuits associated with depression symptoms

      Is this the end of one-size-fits-all treatments for depression?

      Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.